OAM
RXRX icon

Oxford Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Oxford Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$220K Buy
71,753
+42,244
+143% +$163K 0.09% 322
2025
Q4 		$121K Buy
+29,509
New +$146K 0.04% 432

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Oxford Asset Management's RXRX Position: Q1 2026 in Review

Oxford Asset Management increased its Recursion Pharmaceuticals (RXRX) stake by 143% in Q1 2026, buying an estimated $163K and bringing the position to 71,753 shares worth $220K. The position accounts for 0.09% of the portfolio, ranked #322.

Oxford Asset Management first reported a position in RXRX in Q4 2025 and has held it in 2 quarters since. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Oxford Asset Management held 71,753 shares of Recursion Pharmaceuticals worth $220K as of Q1 2026.
  • Oxford Asset Management bought 42,244 Recursion Pharmaceuticals shares in Q1 2026, an estimated $163K.
  • Recursion Pharmaceuticals made up 0.09% of Oxford Asset Management's portfolio in Q1 2026, its #322 holding.
  • Oxford Asset Management first reported a position in Recursion Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Oxford Asset Management's 13F filing for Q1 2026, filed 15 May 2026.